JP2019519533A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519533A5
JP2019519533A5 JP2018561938A JP2018561938A JP2019519533A5 JP 2019519533 A5 JP2019519533 A5 JP 2019519533A5 JP 2018561938 A JP2018561938 A JP 2018561938A JP 2018561938 A JP2018561938 A JP 2018561938A JP 2019519533 A5 JP2019519533 A5 JP 2019519533A5
Authority
JP
Japan
Prior art keywords
composition
yap
subject
gls1
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018561938A
Other languages
English (en)
Japanese (ja)
Other versions
JP7079937B2 (ja
JP2019519533A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034420 external-priority patent/WO2017205595A1/en
Publication of JP2019519533A publication Critical patent/JP2019519533A/ja
Publication of JP2019519533A5 publication Critical patent/JP2019519533A5/ja
Priority to JP2022079875A priority Critical patent/JP7411967B2/ja
Application granted granted Critical
Publication of JP7079937B2 publication Critical patent/JP7079937B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018561938A 2016-05-26 2017-05-25 肺血管疾患を治療するための組成物および方法 Active JP7079937B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022079875A JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341848P 2016-05-26 2016-05-26
US62/341,848 2016-05-26
PCT/US2017/034420 WO2017205595A1 (en) 2016-05-26 2017-05-25 Compositions and methods for treating pulmonary vascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022079875A Division JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019519533A JP2019519533A (ja) 2019-07-11
JP2019519533A5 true JP2019519533A5 (cg-RX-API-DMAC7.html) 2020-06-25
JP7079937B2 JP7079937B2 (ja) 2022-06-03

Family

ID=60412630

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561938A Active JP7079937B2 (ja) 2016-05-26 2017-05-25 肺血管疾患を治療するための組成物および方法
JP2022079875A Active JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022079875A Active JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Country Status (7)

Country Link
US (2) US10925869B2 (cg-RX-API-DMAC7.html)
EP (2) EP3463574B1 (cg-RX-API-DMAC7.html)
JP (2) JP7079937B2 (cg-RX-API-DMAC7.html)
KR (2) KR102434879B1 (cg-RX-API-DMAC7.html)
CN (2) CN115192719B (cg-RX-API-DMAC7.html)
AU (1) AU2017270092B2 (cg-RX-API-DMAC7.html)
WO (1) WO2017205595A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3463574B1 (en) * 2016-05-26 2021-11-03 University of Pittsburgh- Of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
WO2019104038A1 (en) * 2017-11-22 2019-05-31 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
JP7156856B2 (ja) * 2018-08-21 2022-10-19 国立大学法人富山大学 抗肥満剤
EP3690108B1 (en) 2019-02-01 2021-05-12 LG Electronics Inc. Laundry treating apparatus
EP3690109B1 (en) 2019-02-01 2021-05-05 LG Electronics Inc. Laundry treating apparatus
EP3690110B1 (en) 2019-02-01 2021-06-02 LG Electronics Inc. Laundry treating apparatus
US20220233535A1 (en) * 2019-05-05 2022-07-28 Georgetown University Use of inhibitors of yap/taz for the treatment of cancer
WO2020247366A1 (en) * 2019-06-05 2020-12-10 University Of Georgia Research Foundation Compositions and methods for preventing or treating human immunodeficiency virus associated pulmonary arterial hypertension
JP7514508B2 (ja) * 2020-05-19 2024-07-11 国立大学法人鳥取大学 胆道がん治療薬
US20240082158A1 (en) * 2020-05-21 2024-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
CN116421591A (zh) * 2023-05-10 2023-07-14 哈尔滨医科大学大庆分校 Ldha抑制剂在制备治疗肺动脉高压的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5798345A (en) 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5707608A (en) 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US20090202540A1 (en) * 2008-02-11 2009-08-13 Auspex Pharmaceuticals, Inc. Substituted oxazaphosphorines
US8741861B2 (en) 2008-03-27 2014-06-03 Vascular Biosciences Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
KR100963435B1 (ko) 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20170226507A1 (en) * 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
US20160058759A1 (en) * 2014-07-03 2016-03-03 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
US10517844B2 (en) * 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
AU2016219161A1 (en) 2015-02-12 2017-08-31 The Johns Hopkins University Inhibition of Yap for breaking tumor immune tolerance
US20180311353A1 (en) 2015-07-02 2018-11-01 Children's Medical Center Corporation Triplet-triplet annihilation-based upconversion
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
EP3463574B1 (en) * 2016-05-26 2021-11-03 University of Pittsburgh- Of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
WO2019104038A1 (en) * 2017-11-22 2019-05-31 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition

Similar Documents

Publication Publication Date Title
JP2019519533A5 (cg-RX-API-DMAC7.html)
SA521422270B1 (ar) Apol1 مثبطات لـ وطرق لاستخدامها
JP2014507446A5 (cg-RX-API-DMAC7.html)
CN109890390A (zh) Hedgehog通路抑制剂在治疗纤维化疾病中的应用
JP2015024998A5 (cg-RX-API-DMAC7.html)
JP2015508749A5 (cg-RX-API-DMAC7.html)
CN114555588A (zh) 作为axl抑制剂的喹唑啉类化合物
JP2017141277A5 (cg-RX-API-DMAC7.html)
JP2019510081A5 (cg-RX-API-DMAC7.html)
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
JP2020502047A5 (cg-RX-API-DMAC7.html)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
MX2018004043A (es) Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
JP2017530163A5 (cg-RX-API-DMAC7.html)
EP3999121A4 (en) Treatment/prevention of disease by linc complex inhibition
CO2021010415A2 (es) Inhibidor jak y método de preparación del mismo
JPWO2023195530A5 (cg-RX-API-DMAC7.html)
JP2017505809A5 (cg-RX-API-DMAC7.html)
CN111788197A (zh) 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途
JP2016532632A5 (cg-RX-API-DMAC7.html)
JP2017518982A5 (cg-RX-API-DMAC7.html)
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途
JP2016531846A5 (cg-RX-API-DMAC7.html)